Disclosed are methods and apparatuses for manufacturing a solid formulation for oral administration, comprising an edible substrate portion on which a composition comprising a first pharmaceutical active ingredient is deposited, and solid formulations made thereby. The methods comprise providing an edible substrate in the form of a film comprising a plurality of portions, spraying a liquid formulation comprising the active ingredient and a solvent onto an edible substrate portion and evaporating the solvent to form a solid composition deposited on the edible substrate portion; measuring the quantity of active ingredient supported by the edible substrate portion and comparing to a predetermined value, and dividing the edible substrate into the plurality of portions.

Disclosed are methods and apparatuses for manufacturing a solid formulation for oral administration, comprising an edible substrate portion on which a composition comprising a first pharmaceutical active ingredient is deposited, and solid formulations made thereby. The methods comprise providing an edible substrate in the form of a film comprising a plurality of portions, spraying a liquid formulation comprising the active ingredient and a solvent onto an edible substrate portion and evaporating the solvent to form a solid composition deposited on the edible substrate portion; measuring the quantity of active ingredient supported by the edible substrate portion and comparing to a predetermined value, and dividing the edible substrate into the plurality of portions.

An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg is disclosed. The dosage unit consists of: (a) 5-100 wt. % of coated particles comprising 50-99 wt. % of a core particle and 1-50 wt. % of a coating that envelops the core particle, said coating consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-50 wt. % of buffering agent; 15-80 wt. % of branched glucan; 0-78 wt. % of other pharmaceutically acceptable ingredients; and (b) 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 20 μg of the partus control substance and having a pH buffer range of 3.5-5.7.

The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: 1-100 wt. % of particles consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-70 wt. % of buffering agent; 20-94 wt. % of branched glucan; 0-70 wt. % of other pharmaceutically acceptable ingredients; 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 5 μg of the partus control substance and having a pH buffer range of 3.5-5.7. The solid dosage unit of the present invention is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. Furthermore, the dosage unit does not need to be stored and distributed under temperature controlled conditions.

The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide or protein drugs with advantageously high bioavailability, safety and cost-effectiveness. In particular, the invention provides a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa for use as a medicament, wherein said peptide or protein drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex, and with a pharmaceutically acceptable reducing agent. The invention also provides a pharmaceutical composition comprising: a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex; and a pharmaceutically acceptable reducing agent.

This disclosure provides methods of using compounds that act to increase oxytocin release, including certain melanocortin receptor agonists, for treating or reducing the severity of psychotherapeutic or social disorders such as autism, and in particular the use of these compounds as an adjunct to psychotherapeutic counseling or behavioral therapy.

The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

The present invention relates to a novel pharmaceutical use of bromide, i.e. the treatment of autism spectral disorder (ASD).

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.

Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.